These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22087064)

  • 1. Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates.
    Muratore M; Quarta E; Grimaldi A; Calcagnile F; Quarta L
    Drug Des Devel Ther; 2011; 5():445-54. PubMed ID: 22087064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
    Sartori L; Adami S; Filipponi P; Crepaldi G
    Aging Clin Exp Res; 2003 Aug; 15(4):271-83. PubMed ID: 14661816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and osteoporosis treatment in Italy.
    Gennari C; Reginster JY
    Aging (Milano); 1998 Aug; 10(4):284-94. PubMed ID: 9825019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy.
    Elomaa I; Blomqvist C
    Acta Oncol; 1995; 34(5):629-36. PubMed ID: 7546830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates in osteoporosis: recent clinical experience.
    McClung MR
    Expert Opin Pharmacother; 2000 Jan; 1(2):225-38. PubMed ID: 11249544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The successful development of bisphosphonates in the therapy of osteoporosis].
    Fassbender WJ; Stumpf UC; Kurth A
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
    Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
    Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for the use of clodronate in osteoporosis.
    Kanis JA; McCloskey EV; Sirtori P; Khan S; Fern D; Eyres K; Aaron J; Beneton MN
    Osteoporos Int; 1993; 3 Suppl 2():S23-8. PubMed ID: 8481595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate therapy.
    Licata AA
    Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisphosphonates for osseus invasion caused by bronchial carcinoma].
    Bartl R
    Dtsch Med Wochenschr; 2008 Nov; 133(48):2530. PubMed ID: 19021088
    [No Abstract]   [Full Text] [Related]  

  • 11. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of osteoporosis with bisphosphonates.
    Watts NB
    Rheum Dis Clin North Am; 2001 Feb; 27(1):197-214. PubMed ID: 11285996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.
    McClung MR
    Bone; 1996 Nov; 19(5 Suppl):195S-198S. PubMed ID: 8922662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates.
    McClung M
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):735-44. PubMed ID: 17117298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clodronate and osteoporosis.
    Kanis JA; McCloskey EV; Beneton MN
    Maturitas; 1996 May; 23 Suppl():S81-6. PubMed ID: 8865146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders.
    Ghinoi V; Brandi ML
    Expert Opin Pharmacother; 2002 Nov; 3(11):1643-56. PubMed ID: 12437497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bisphosphonates. Drugs for the treatment of disorders of calcium and bone metabolism].
    Warneke G; Henning HV
    Internist (Berl); 1992 Jun; 33(6):441-5. PubMed ID: 1385800
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.